Press Release

Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *